2021亚太玻璃体视网膜学会新生血管性AMD的治疗和延长方案专家共识解读  

Interpretation of the 2021 Asia-Pacific Vitreo-Retina Society Expert Consensus on the Treat-and-Extend Protocol for nAMD

作　　者：孙隽然 孙晓东[1] Sun Junran;Sun Xiaodong(Department of Ophthalmology,Shanghai General Hospital,Shanghai 200080,China)

机构地区：[1]上海市第一人民医院眼科,上海200080

出　　处：《中华实验眼科杂志》2025年第1期9-17,共9页Chinese Journal Of Experimental Ophthalmology

摘　　要：治疗-延长(T&E)方案是临床常用的抗血管内皮生长因子(VEGF)药物治疗新生血管性年龄相关性黄斑变性(nAMD)方案之一,可以在有效改善视力的同时延长治疗间隔、减少就诊次数。面对亚太地区医疗资源有限、患者治疗依从性不佳,T&E方案具有独特的优势。然而目前亚太地区临床使用抗VEGF药物缺乏规范化的治疗路径,尚缺乏关于T&E方案的指南。2021年亚太玻璃体视网膜学会专家组(APVRS)回顾并总结抗VEGF药物T&E方案临床研究,结合临床实践情况制定一组关于在亚太地区使用T&E方案治疗nAMD的共识。本文就APVRS专家组提出的最新T&E治疗方案进行解读以指导临床医师规范治疗。The treat-and-extend(T&E)protocol for treating neovascular age-related macular degeneration(nAMD)is one of the commonly used anti-vascular endothelial growth factor(VEGF)treatment strategies in clinical practice.It effectively improves vision while extending treatment intervals and reducing the number of clinic visits.In the Asia-Pacific region,where medical resources are limited and patient compliance is often poor,the T&E protocol offers unique advantages.However,there are currently no guidelines on the T&E protocol in this region,and its clinical use lacks standardized treatment pathways.In 2021,the Asia-Pacific Vitreo-Retina Society(APVRS)expert panel reviewed and summarized clinical research on the anti-VEGF T&E protocol,combining this with clinical practice to develop a set of consensus recommendations for using the T&E protocol to treat nAMD in the Asia-Pacific region.This article reviews and interprets the latest T&E treatment protocol proposed by the APVRS expert panel to guide clinicians in standardized treatment.

关 键 词：新生血管性年龄相关性黄斑变性 血管生成抑制剂 治疗-延长方案 亚太玻璃体视网膜学会专家组 共识解读 

分 类 号：R774.5[医药卫生—眼科]